Drugs / IZASTOBART
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04947033 | Dec 2023 → Dec 2024 | neoplasm | I-Mab Biopharma US Limited | Unknown | No outcome recorded |
| Phase 1 | NCT04678921 | Dec 2020 → Nov 2022 | metastatic malignant neoplasm | I-Mab Biopharma US Limited | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT05511350 Background | — | metastatic malignant neoplasm | I-Mab Biopharma US Limited | No longer available | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IZASTOBART | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314842 ↗ |
| Known as | TJ210001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05511350 ↗ |
| Modality | Monoclonal antibody | “human anti-C5aR monoclonal antibody” NCT04678921 ↗ |